Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey
-
Published:2023-04-04
Issue:9
Volume:38
Page:3035-3042
-
ISSN:0931-041X
-
Container-title:Pediatric Nephrology
-
language:en
-
Short-container-title:Pediatr Nephrol
Author:
Zurowska AleksandraORCID, Drozynska-Duklas MagdalenaORCID, Topaloglu RezanORCID, Bouts AntoniaORCID, Boyer OliviaORCID, Shenoy MohanORCID, Vivarelli MarinaORCID, Alpay H., Andersen R., Ariceta G., Atmış B., Bayrakçı U. S., Esrea B., Baudouin V., Bervina N., Benetti E., Berard E., Bjerre A., Christian M., Couderc A., Dehoorne J., Deschenes G., Dossier C., Düşünsel R., Ekinci Z., Emma F., Espinoza L., Gianviti A., Herrero Goñi M., Guido G., Ghio L., Groothoff J., Hacıhamdioğlu D. Ö., Espino Hernández M., Jankauskiene A., Kagan M., Kemper M., Kovacevic M., Kohl S., Kramar R. T., López-González M., Aris A. M., Maringhini S., Marlais M., Melgosa M., Mitsioni A., Montini G., Moczulska A., Murer L., Obukhova V., Oh J., Ortega P., Özçakar Z. B., Ulinski T., Pasini A., Papalia T., Paunova S., Pena A., Pecoraro C., Petrosyan E., Peruzzi L., Printza N., Prikhodina L., Pietrement C., Rittig S., Rodrigo D., Savenkova N., Saraga M., Sever F. L., Schreuder M., Szczepanska M., Tasic V., Tonshoff B., Tullus K., Vara J., Vande Walle J., Volokhina E., Zieg J., Waters A., Weber L. T., Webbe N., Wasiak M., Endén K., Tsygin A., Grenda R., Raes A., Van Hoeck Koen J. M., Adams B., Aksenova M., Ranchin B., Hooman N., Ogarek I., Seeman T., Fila M., Oni L., Mir S., Novo R., Stabouli S., Vara-Martín J., van Wijk J. A. E., Ehren R., Bekassy Z., Herthelius M., Becherucci F., Shasha-Lavsky H., Santos F., Feldkötter M., Pańczyk-Tomaszewska M., Harambat J., Grima D., Gökçe I., Teixeira A., Licht C., Schmidt I. M., Brandström P., Dinçel N.,
Abstract
Abstract
Background
There is paucity of information on rituximab-associated hypogammaglobulinemia (HGG) and its potential infectious consequences in children treated for idiopathic nephrotic syndrome (INS).
Methods
A survey was distributed by the European Society Pediatric Nephrology to its members. It addressed the screening and management practices of pediatric nephrology units for recognizing and treating RTX-associated HGG and its morbidity and mortality. Eighty-four centers which had treated an overall 1328 INS children with RTX responded.
Results
The majority of centers administered several courses of RTX and continued concomitant immunosuppressive therapy. Sixty-five percent of centers routinely screened children for HGG prior to RTX infusion, 59% during, and 52% following RTX treatment. Forty-seven percent had observed HGG prior to RTX administration, 61% during and 47% >9 months following treatment in 121, 210, and 128 subjects respectively. Thirty-three severe infections were reported among the cohort of 1328 RTX-treated subjects, of whom 3 children died. HGG had been recognized in 30/33 (80%) of them.
Conclusions
HGG in steroid-dependent/frequently relapsing nephrotic syndrome (SDNS/FRNS) children is probably multifactorial and can be observed prior to RTX administration in children with SDNS/FRNS. Persistent HGG lasting >9 months from RTX infusion is not uncommon and may increase the risk of severe infections in this cohort. We advocate for the obligatory screening for HGG in children with SDNS/FRNS prior to, during, and following RTX treatment. Further research is necessary to identify risk factors for developing both HGG and severe infections before recommendations are made for its optimal management.
Graphical abstract
Publisher
Springer Science and Business Media LLC
Subject
Nephrology,Pediatrics, Perinatology and Child Health
Reference37 articles.
1. Payandeh Z, Bahrami AA, Hoseinpoor R, Mortazavi Y, Rajabibazl M, Rahimpour A et al (2019) The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother 109:2415–2426. https://doi.org/10.1016/j.biopha.2018.11.121 2. Kronbichler A, Windpessl M, Pieringer H, Jayne DRW (2017) Rituximab for immunologic renal disease: what the nephrologist needs to know. Autoimmun Rev 16:633–643. https://doi.org/10.1016/j.autrev.2017.04.007 3. Ravani P, Bonanni A, Rossi R, Caridi G, Ghiggeri GM (2016) Anti-CD20 antibodies for idiopathic nephrotic syndrome in children. Clin J Am Soc Nephrol 11:710–720. https://doi.org/10.2215/CJN.08500815 4. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K et al (2014) Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273–1281. https://doi.org/10.1016/S0140-6736(14)60541-9 5. Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M et al (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259–2266. https://doi.org/10.1681/ASN.2014080799
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|